enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. How a new FDA-approved drug can — and can’t — help people ...

   www.aol.com/fda-approved-drug-t-help-121600044.html

   In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...

3. Alzheimer's: Are newly approved drugs making a real-life ...

   www.aol.com/alzheimers-newly-approved-drugs...

   The FDA granted accelerated approval to aducanumab for the treatment of Alzheimer’s disease in 2021 based on its ability to clear amyloid plaques. While aducanumab was successful in clearing ...

4. A Revolutionary New Alzheimer’s Drug Was Just Approved by the ...

   www.aol.com/revolutionary-alzheimer-drug-just...

   Lecanemab (a.k.a. leqembi) has received full approval from the U.S. Food and Drug Administration. This is the first FDA-approved treatment to help slow the progression of Alzheimer’s disease.

5. Aducanumab - Wikipedia

   en.wikipedia.org/wiki/Aducanumab

   [10] [11] [12] The FDA stated that it represents a first-of-its-kind treatment approved for Alzheimer's disease and that it is the first new treatment approved for Alzheimer's since 2003. [3] Aducanumab's approval is controversial for numerous reasons including ambiguous clinical trial results regarding efficacy , the high cost of the ...

6. Anti-amyloid drugs - Wikipedia

   en.wikipedia.org/wiki/Anti-amyloid_drugs

   [13] [14] [15] The FDA stated that it represents a first-of-its-kind treatment approved for Alzheimer's disease and that it is the first new treatment approved for Alzheimer's since 2003. [6] Aducanumab's approval is controversial for numerous reasons including ambiguous clinical trial results regarding efficacy , the high cost of the ...

7. FDA grants full approval to new Alzheimer's drug meant to ...

   www.aol.com/news/fda-grants-full-approval...

   Leqembi was approved for people with mild cognitive impairment or early-stage Alzheimer's disease. The drug is given intravenously every two weeks, meaning patients will need to go to a hospital ...